8-K: Altimmune Reports Strong Q2, Pemvidutide Shines in MASH Trial

Altimmune, Inc. announced positive second quarter 2025 financial results and significant advancements in its pemvidutide clinical programs, particularly for MASH.

Summary

• Altimmune reported cash, cash equivalents, and short-term investments of $183.1 million as of June 30, 2025, a 39% increase from $131.9 million at December 31, 2024.
• Net loss for the second quarter ended June 30, 2025, was $22.1 million, or $0.27 per share, an improvement from a net loss of $24.6 million, or $0.35 per share, in the same period of 2024.
• Research and development expenses decreased to $17.2 million for Q2 2025, down from $21.2 million in Q2 2024, primarily due to the timing of clinical trial costs.
• Positive 24-week top-line data from the IMPACT Phase 2b trial for pemvidutide in MASH showed statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of patients.
• The IMPACT trial also demonstrated statistically significant weight loss of up to 6.2% at 24 weeks, with a trajectory of continuing weight loss.
• New data from the IMPACT trial revealed potentially class-leading improvements in corrected T1 (cT1), an MRI-based marker of liver inflammation and fibrosis, with mean decreases of 145.0 ms and 147.9 ms in pemvidutide groups versus 27.5 ms in placebo.
• Pemvidutide showed potentially best-in-class tolerability in the IMPACT trial, with less than 1% treatment discontinuations due to adverse events.
• The company initiated two new Phase 2 trials for pemvidutide: RECLAIM for Alcohol Use Disorder (AUD) in May 2025 and RESTORE for Alcohol-Associated Liver Disease (ALD) in July 2025.
• Jerry Durso was appointed Chairman of Altimmune's Board of Directors, succeeding Mitchel Sayare, Ph.D., as part of ongoing succession planning.

Sentiment

Score: 9

Explanation: The filing presents very strong positive clinical trial data for pemvidutide in MASH, including statistically significant MASH resolution, weight loss, and 'potentially class-leading' improvements in liver markers with excellent tolerability. Financially, the company improved its net loss and significantly increased its cash position, providing a solid runway for future development. The expansion into new indications (AUD, ALD) further enhances the pipeline's value. These factors collectively indicate a highly positive outlook.

Positives

• Cash, cash equivalents, and short-term investments increased by 39% to $183.1 million as of June 30, 2025, providing a strong financial runway.
• Net loss decreased to $22.1 million ($0.27 per share) in Q2 2025 from $24.6 million ($0.35 per share) in Q2 2024, indicating improved financial performance.
• Pemvidutide achieved statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of patients in the IMPACT Phase 2b trial.
• Statistically significant weight loss of up to 6.2% was observed at 24 weeks in the IMPACT trial, with a continuing weight loss trajectory.
• New cT1 imaging data from the IMPACT trial showed mean decreases of 145.0 ms and 147.9 ms in pemvidutide groups, demonstrating potentially class-leading improvements in liver inflammation and fibrosis markers.
• Pemvidutide exhibited potentially best-in-class tolerability in the IMPACT trial, with less than 1% treatment discontinuations due to adverse events.
• The initiation of Phase 2 trials for pemvidutide in Alcohol Use Disorder (RECLAIM) and Alcohol-Associated Liver Disease (RESTORE) expands the drug's potential indications and pipeline.

Negatives

• The company continues to report a net loss, totaling $22.1 million for the quarter.
• Interest income decreased to $1.1 million in Q2 2025 from $2.182 million in Q2 2024.
• Weighted-average common shares outstanding increased to 81,477,548 in Q2 2025 from 70,924,371 in Q2 2024, indicating shareholder dilution.

Risks

• Delays in regulatory review processes for product candidates.
• Potential manufacturing and supply chain interruptions.
• Challenges in accessing clinical sites and patient enrollment for trials.
• Adverse effects on healthcare systems and disruption of the global economy.
• Uncertainty regarding the reliability of study results concerning human safety and potential adverse effects of product candidates.
• The company's ability to manufacture clinical trial materials on anticipated timelines.
• The success of future product advancements, including the outcomes of future clinical trials.

Future Outlook

The company is preparing for an End-of-Phase 2 Meeting with the FDA for pemvidutide in MASH, targeted for the fourth quarter of 2025, which will position it for Phase 3 development. Full 48-week data from the IMPACT trial is also expected in the fourth quarter of 2025. Additionally, pemvidutide is advancing in Phase 2 trials for Alcohol Use Disorder (RECLAIM) and Alcohol-Associated Liver Disease (RESTORE).

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer, stated: 'Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial. We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development.'
• Dr. Scott Harris, Chief Medical Officer, commented: 'The improvements in cT1 observed in the IMPACT trial were potentially class-leading among MASH clinical trials to-date. Reductions in cT1 are correlated with MASH resolution and fibrosis improvement. These new data along with the previously reported results from non-invasive tests of fibrosis, further strengthen the potential therapeutic value of pemvidutide.'

Industry Context

Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist, is positioned in the highly competitive and rapidly evolving market for metabolic and liver diseases, particularly MASH and obesity. The positive 24-week data from the IMPACT trial, especially the statistically significant MASH resolution, weight loss, and 'potentially class-leading' cT1 improvements, suggest pemvidutide could be a highly differentiated therapy. Its reported 'best-in-class tolerability' is a significant advantage in a class of drugs often associated with gastrointestinal side effects. The expansion into Alcohol Use Disorder and Alcohol-Associated Liver Disease further diversifies its potential market reach within the cardiometabolic and liver disease space.

Comparison to Industry Standards

• Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks, setting a high benchmark for early-stage MASH therapies.
• The observed mean decreases in corrected T1 (cT1) relaxation time (145.0 ms and 147.9 ms in pemvidutide groups vs. 27.5 ms in placebo) are highlighted as 'potentially class-leading improvements' among MASH clinical trials to date, indicating strong efficacy in reducing liver inflammation and fibrosis.
• The tolerability profile, with less than 1% treatment discontinuations due to adverse events, is described as 'potentially best-in-class' among drugs in development for MASH, which could provide a competitive edge over other GLP-1 agonists that sometimes face higher discontinuation rates due to side effects.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Positive impact due to strong clinical trial results for pemvidutide, which could increase the drug's market potential and company valuation. The reduction in net loss and significant increase in cash reserves also provide financial stability. However, the increase in shares outstanding indicates dilution from a recent capital raise.
• **Patients (MASH, AUD, ALD, Obesity)**: Highly positive impact as pemvidutide shows promising efficacy and tolerability, potentially offering a new, differentiated treatment option for significant unmet medical needs.
• **Employees**: Positive impact due to the company's strong clinical progress and improved financial position, suggesting stability and potential for growth.
• **Investment Professionals/Analysts**: Provides clear, positive data points for valuation models and investment recommendations, particularly regarding pemvidutide's competitive profile in the MASH and cardiometabolic space.
• **Regulatory Authorities (FDA)**: The positive 24-week data and planned End-of-Phase 2 meeting indicate active engagement and progress towards regulatory milestones for pemvidutide.

Next Steps

• End-of-Phase 2 Meeting with the FDA for pemvidutide in MASH, targeted for Q4 2025.
• Reporting of full 48-week data from the IMPACT Phase 2b MASH trial in Q4 2025.
• Continued advancement of pemvidutide into Phase 3 development for MASH.
• Ongoing Phase 2 RECLAIM trial for Alcohol Use Disorder (AUD).
• Ongoing Phase 2 RESTORE trial for Alcohol-Associated Liver Disease (ALD).

Key Dates

Recommendation

The filing presents exceptionally strong clinical data for pemvidutide in MASH, demonstrating statistically significant resolution, meaningful weight loss, and 'potentially class-leading' improvements in liver markers with an excellent tolerability profile. This positions pemvidutide as a highly differentiated and competitive asset in a large and growing market. Financially, the company has significantly bolstered its cash reserves and reduced its net loss, providing a strong runway for continued development into Phase 3. The expansion into AUD and ALD further diversifies the pipeline. Given the compelling clinical efficacy, favorable safety profile, and improved financial health, Altimmune represents a strong investment opportunity with significant upside potential.

Keywords

Biopharmaceutical, MASH, GLP-1, glucagon, obesity, liver disease, clinical trial, pemvidutide, Alcohol Use Disorder, Alcohol-Associated Liver Disease, Phase 2b, financial results